NewsBenzingaLeerink Partners维持对Cytokinetics的“跑赢大盘”评级，将目标价下调至100美元 Leerink Partners维持对Cytokinetics的“跑赢大盘”评级，将目标价下调至100美元 Benzinga 2026.11.05 19:16 (GMT+0) Open on Benzinga Other news UBS Maintains Buy on CDW, Raises Price Target to $195 UBS Maintains Buy on Addus HomeCare, Raises Price Target to $160 UBS Maintains Neutral on Qualcomm, Lowers Price Target to $180 UBS Maintains Neutral on HubSpot, Lowers Price Target to $240 UBS Maintains Buy on Edwards Lifesciences, Raises Price Target to $118 UBS Maintains Buy on Amplitude, Raises Price Target to $22
